{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:17:49Z","timestamp":1762870669172,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T00:00:00Z","timestamp":1499385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.mayocpiqo.2017.06.002","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T19:46:06Z","timestamp":1501703166000},"page":"161-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Monoclonal Gammopathy of Undetermined Significance"],"prefix":"10.1016","volume":"1","author":[{"given":"Ronald S.","family":"Go","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert C.","family":"Heien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey R.","family":"Sangaralingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth B.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilay D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mayocpiqo.2017.06.002_bib1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/leu.2015.336","article-title":"Clinical prevalence (diagnosed cases) of monoclonal gammopathy of undetermined significance in the US: estimating the burden on health care","volume":"30","author":"Go","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2017.06.002_bib2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A\u00a0long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2017.06.002_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clml.2014.09.004","article-title":"Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis","volume":"15","author":"Go","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2017.06.002_bib4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","article-title":"The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma","volume":"1","author":"Sigurdardottir","year":"2015","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2017.06.002_bib5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2010.08089.x","article-title":"Monoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma [letter]?","volume":"149","author":"Go","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2017.06.002_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2141.2009.07807.x","article-title":"UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)","volume":"147","author":"Bird","year":"2009","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2017.06.002_bib7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2017.06.002_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2141.2010.08207.x","article-title":"Monoclonal gammopathy of undetermined significance: a consensus statement","volume":"150","author":"Berenson","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2017.06.002_bib9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network","volume":"99","author":"van de Donk","year":"2014","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2017.06.002_bib10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff (Millwood)"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2017.06.002_bib11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2017.06.002_bib12","first-page":"27","article-title":"Established populations for epidemiologic studies of the elderly: study design and methodology","volume":"5","author":"Cornoni-Huntley","year":"1993","journal-title":"Aging (Milano)"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2017.06.002_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.5858\/1999-123-0106-GFCALE","article-title":"Guidelines for clinical and laboratory evaluation of patients with monoclonal gammopathies","volume":"123","author":"Keren","year":"1999","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2017.06.002_bib14","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2010-04-277566","article-title":"Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications","volume":"116","author":"Bianchi","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2017.06.002_bib15","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.mayocpiqo.2017.06.002_bib16","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N\u00a0Engl J Med"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S254245481730036X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S254245481730036X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:07:26Z","timestamp":1762870046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S254245481730036X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S254245481730036X"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2017.06.002","relation":{},"ISSN":["2542-4548"],"issn-type":[{"type":"print","value":"2542-4548"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal Gammopathy of Undetermined Significance","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2017.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}